New anti-clotting medication reduces bleeding among people with atrial fibrillation
November 13, 2023
November 13, 2023
DALLAS, Texas, Nov. 13 [Category: Health Care] -- The American Heart Association issued the following news release:
Research Highlights:
Bleeding was reduced by more than 60% among people taking the anti-clotting agent abelacimab, demonstrating its safety for people at risk of stroke from atrial fibrillation.
Abelacimab was compared with another standard-of-care anti-clotting medication -- rivaroxaban -- for occurrence of bleeding in a study of more than 1, . . .
Research Highlights:
Bleeding was reduced by more than 60% among people taking the anti-clotting agent abelacimab, demonstrating its safety for people at risk of stroke from atrial fibrillation.
Abelacimab was compared with another standard-of-care anti-clotting medication -- rivaroxaban -- for occurrence of bleeding in a study of more than 1, . . .